Posts Feed
Comments Feed

Archive for the 'Prostate' Category

Seed Displacements After Permanent Brachytherapy For Prostate Cancer In Dependence On The Prostate Level

Jan 3rd 2009Drug InformationProstate

UroToday.com - Interstitial brachytherapy became an established treatment for localized prostate cancer in the last decade with excellent long-term results. CT-based dosimetry is currently recommended as the standard for postimplant dosimetry, with a suggested interval of four weeks after I-125 brachytherapy. For practical and logistic reasons many brachytherapists prefer to rely on early scanning.

More: continued here

No Comments »

CHMP Recommends Granting Marketing Authorisation For FIRMAGON(R) (degarelix) For Treatment Of Prostate Cancer

Jan 3rd 2009Drug InformationProstate

Ferring Pharmaceuticals received notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer.

More: continued here

No Comments »

FDA Approves Ferring Pharmaceuticals’ Degarelix (Generic Name) For Treatment Of Advanced Prostate Cancer

Jan 3rd 2009Drug InformationProstate

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA. Following issuance of a trade name, Ferring Pharmaceuticals, USA will immediately begin commercialization in the U.S.

More: continued here

No Comments »

« Prev - Next »

1